Novel Therapies May Lead to More Treatment Options in Sarcoma Subtypes
A number of developments are taking place within sarcoma subtypes that may have the potential to impact the standard of care in select patient subgroups, bolstering the armamentarium and potentially resolving unmet needs, according to Sandra P. D’Angelo, MD.
This includes CAR T-cell therapies such as a famitresgene autoleucel (afami-cel), which was investigated in a phase 2 trial (NCT04044768) in a population of patients with advanced synovial sarcoma or myxoid round cell liposarcoma.1 D’Angelo indicated that the product has the potential to become a standard of care in the synovial sarcoma population.
D’Angelo, a sarcoma oncologist and cellular therapist at Memorial Sloan Kettering Cancer Center, discussed how envafolimab may hold promise in undifferentiated pleomorphic sarcoma (UPS) and expanded on the potential of immune checkpoint inhibitors in dedifferentiated liposuction.
A phase 2 trial [utilizing] afami-cel trial has been conducted and completed. Afami-cel targets MAGE-A4, and was found to be quite promising, specifically [in] synovial sarcoma. We’re optimistic that perhaps it’ll become a new standard of care for patients with synovial sarcoma.
We don’t have many immunotherapy approvals other than atezolizumab [Tecentriq] for alveolar soft-tissue sarcoma, but there’s also an ongoing trial called the phase 2 ENVASARC [NCT04480502] that utilizes checkpoint blockade envafolimab in UPS.2 That trial has the prospect of allowing envafolimab to ultimately be FDA-approved.
ارسال به دوستان